Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 119, Issue 10, 2012, Pages 1162-1170

  Chattopadhyay, S ^a   Galaal, K A ^a   Patel, A ^a   Fisher, A ^a   Nayar, A ^b   Cross, P ^a   Naik, R ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b Princess Royal University Hospital   (United Kingdom)

Author keywords

Depth of myometrial invasion; endometrial cancer; nodal involvement; survival; tumour free distance

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; DEPTH OF INVASION; DISEASE SPECIFIC SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIOID ENDOMETRIAL CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIAL INVASION; ONCOLOGICAL PARAMETERS; PELVIS LYMPHADENECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SEROSA; TUMOR FREE DISTANCE;

AGE OF ONSET; AGED; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PELVIS; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SEROUS MEMBRANE;

EID: 84865139637     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2012.03427.x     Document Type: Article

References (22)

1. Zaino RJ, Kurman RJ, Diana KL, Morrow CP,. Pathologic models to predict outcome for women with endometrial adenocarcinoma-importance of the distinction between surgical stage and clinical stage-a Gynecologic Oncology Group study. Cancer 1996; 77: 1115-21. (Pubitemid 26080902)
2. Prat J,. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004; 35: 649-62. (Pubitemid 38881074)
3. Larson DM, Connor GP, Broste SK, et al. Prognostic significance of gross myometrial invasion with endometrial cancer. Obstet Gynecol 1996; 88: 394-8. (Pubitemid 26293285)
4. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC,. Hematogenous dissemination in corpus cancer. Gynecol Oncol 2001; 80: 233-8. (Pubitemid 32158464)
5. Standards and Datasets for Reporting Cancers. The Royal College of Pathologists, London. [http://www.rcpath.org/Resources/RCPath/ Migrated%20Resources/Documents/G/g090datasetendometrialfinaljan2010.pdf]. Last accessed 25 January 2012.
6. Jacques SM, Qureshi F, Munkarah A, Lawrence WD,. Interinstitutional surgical pathology review in gynaecologic oncology: II. Endometrial cancer in hysterectomy specimens. Int J Gynecol Pathol 1998; 17: 42-5. (Pubitemid 28016701)
7. Ali A, Black D, Soslow RA,. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 2007; 26: 115-23. (Pubitemid 46573205)
8. Lindauer J, Fowler JM, Mnolitas TP, Copeland LJ, Eaton LA, Ramirez NC, et al. Is there a prognostic difference between depth of myometrial invasion and tumour-free distance from the uterine serosa in endometrial cancer? Gynecol Oncol 2003; 91: 547-51. (Pubitemid 38388148)
9. Lutz MH, Underwood PB, Kreutner A, Miller MC,. Endometrial carcinoma: a new method of classification of therapeutic and prognostic significance. Gynecol Oncol 1978; 6: 83-94. (Pubitemid 8299233)
10. Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathological findings of a prospective study. Obstet Gynecol 1984; 63: 825-32. (Pubitemid 14105231)
11. Kaku T, Tsuruchi N, Tsukamoto N, Hirakawa T, Kamura T, Nakano H,. Reassessment of myometrial invasion in endometrial carcinoma. Obstet Gynecol 1994; 84: 979-82. (Pubitemid 24360260)
12. Schwab KV, O'Malley DM, Fowler JM, et al. Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma. Gynecol Oncol 2009; 112: 146-9.
13. Kondalsamy-Chennakesavan S, van Vugt S, Sanday K, Nicklin J, et al. Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors for lymph node metastases in endometrial cancer. Int J Gynecol Cancer 2010; 20: 1217-21.
14. Cibula D, Abu-Rustum NR,. Pelvic lymphadenectomy in cervical cancer-surgical anatomy and proposal for a new classification system. Gynecol Oncol 2010; 116: 33-7.
15. The writing committee on behalf of the ASTEC study. Efficacy of systemic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373: 125-36.
16. Zweig MH, Campbell G,. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-77. (Pubitemid 23118304)
17. Obuchowski NA,. Nonparametric analysis of clustered ROC curve data. Biometrics 1997; 53: 567-78. (Pubitemid 27262219)
18. Cirisano F, Robboy S, Dodge R, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999; 74: 285-94.
19. Boruta DM II, Gehrig PA, Fader AN, Olawaiye AB, et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009; 115: 142-53.
20. Protocol for the Examination of Specimens from Patients with Carcinoma of the Endometrium. College of American Pathologists (CAP), Northfield, IL, USA. [http://www.cap.org/apps/docs/committees/cancer/cancer-protocols/2011/ Endometrium-11protocol.pdf]. Last accessed 1 February 2012.
21. Endometrial Cancer Structured Reporting Protocol, 1st edn. Royal College of Pathologists of Australasia, Surry Hills, NSW, Australia, 2011. [http://www.clinicalguidelines.gov.au/browse.php?treePath=&pageType= 2&fldglrID=1835&]. Last accessed 1 March 2012.
22. Chan JK, Kapp DS,. Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 2007; 8: 831-41. (Pubitemid 47321602)